| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytomegalovirus Infections | 44 | 2024 | 465 | 10.760 |
Why?
|
| Antiviral Agents | 66 | 2024 | 1262 | 10.340 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 91 | 2024 | 6814 | 8.870 |
Why?
|
| Respiratory Syncytial Virus Infections | 30 | 2023 | 435 | 8.850 |
Why?
|
| Respiratory Tract Infections | 25 | 2023 | 451 | 8.200 |
Why?
|
| Transplant Recipients | 29 | 2024 | 334 | 6.320 |
Why?
|
| Immunocompromised Host | 36 | 2024 | 711 | 6.150 |
Why?
|
| Cytomegalovirus | 29 | 2024 | 483 | 6.010 |
Why?
|
| Cross Infection | 27 | 2023 | 550 | 4.430 |
Why?
|
| Ribavirin | 13 | 2019 | 180 | 3.620 |
Why?
|
| Virus Diseases | 11 | 2023 | 400 | 3.580 |
Why?
|
| Hematologic Neoplasms | 24 | 2024 | 1930 | 3.220 |
Why?
|
| Drug Resistance, Viral | 11 | 2024 | 74 | 3.040 |
Why?
|
| Paramyxoviridae Infections | 9 | 2021 | 86 | 3.030 |
Why?
|
| Respiratory Syncytial Virus, Human | 8 | 2023 | 211 | 2.350 |
Why?
|
| Neoplasms | 49 | 2023 | 15796 | 2.280 |
Why?
|
| Organophosphonates | 7 | 2020 | 64 | 2.200 |
Why?
|
| Cytosine | 7 | 2020 | 149 | 2.130 |
Why?
|
| Influenza, Human | 12 | 2021 | 957 | 2.080 |
Why?
|
| Infection Control | 12 | 2022 | 279 | 2.000 |
Why?
|
| Anti-Bacterial Agents | 19 | 2022 | 3116 | 1.990 |
Why?
|
| Gram-Positive Bacterial Infections | 8 | 2021 | 161 | 1.930 |
Why?
|
| Respiratory Syncytial Viruses | 6 | 2019 | 171 | 1.910 |
Why?
|
| Bacteremia | 11 | 2016 | 695 | 1.880 |
Why?
|
| Acetates | 9 | 2024 | 118 | 1.860 |
Why?
|
| Aerosols | 5 | 2013 | 167 | 1.690 |
Why?
|
| Disinfection | 5 | 2020 | 39 | 1.680 |
Why?
|
| Pneumonia, Viral | 9 | 2017 | 717 | 1.520 |
Why?
|
| Virus Activation | 9 | 2019 | 231 | 1.520 |
Why?
|
| Cancer Care Facilities | 9 | 2019 | 905 | 1.490 |
Why?
|
| Humans | 213 | 2024 | 271116 | 1.440 |
Why?
|
| Quinazolines | 9 | 2024 | 934 | 1.370 |
Why?
|
| Enzyme-Linked Immunospot Assay | 3 | 2019 | 34 | 1.350 |
Why?
|
| DNA Viruses | 2 | 2020 | 47 | 1.330 |
Why?
|
| Transplantation, Homologous | 18 | 2024 | 2947 | 1.330 |
Why?
|
| Vancomycin-Resistant Enterococci | 2 | 2021 | 18 | 1.330 |
Why?
|
| Communicable Diseases | 3 | 2023 | 210 | 1.330 |
Why?
|
| Adult | 102 | 2024 | 80926 | 1.160 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 8 | 2019 | 210 | 1.140 |
Why?
|
| Aged | 91 | 2024 | 73028 | 1.130 |
Why?
|
| Bacterial Infections | 5 | 2023 | 485 | 1.120 |
Why?
|
| Community-Acquired Infections | 6 | 2021 | 293 | 1.100 |
Why?
|
| Middle Aged | 103 | 2024 | 89687 | 1.050 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 5 | 2012 | 310 | 1.040 |
Why?
|
| Opportunistic Infections | 7 | 2015 | 226 | 1.040 |
Why?
|
| Ultraviolet Rays | 4 | 2020 | 588 | 1.010 |
Why?
|
| DNA, Viral | 5 | 2019 | 673 | 1.010 |
Why?
|
| Vancomycin Resistance | 4 | 2013 | 57 | 0.990 |
Why?
|
| Herpesviridae Infections | 3 | 2016 | 178 | 0.990 |
Why?
|
| Leukemia | 8 | 2021 | 1673 | 0.980 |
Why?
|
| Hospitals | 9 | 2023 | 497 | 0.980 |
Why?
|
| Young Adult | 42 | 2021 | 22298 | 0.970 |
Why?
|
| Enterobacteriaceae | 2 | 2016 | 46 | 0.960 |
Why?
|
| Enterobacteriaceae Infections | 2 | 2016 | 70 | 0.950 |
Why?
|
| Mycobacterium tuberculosis | 3 | 2019 | 470 | 0.940 |
Why?
|
| Vaccination | 5 | 2023 | 1178 | 0.940 |
Why?
|
| Incidence | 22 | 2024 | 5895 | 0.930 |
Why?
|
| Male | 111 | 2024 | 127862 | 0.930 |
Why?
|
| Retrospective Studies | 58 | 2024 | 39746 | 0.920 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2024 | 43 | 0.910 |
Why?
|
| Staphylococcal Infections | 8 | 2019 | 680 | 0.880 |
Why?
|
| Daptomycin | 2 | 2021 | 39 | 0.880 |
Why?
|
| Disease Outbreaks | 7 | 2011 | 428 | 0.870 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2015 | 242 | 0.840 |
Why?
|
| Serratia Infections | 3 | 2011 | 14 | 0.820 |
Why?
|
| Adolescent | 49 | 2021 | 32497 | 0.820 |
Why?
|
| Female | 107 | 2024 | 147682 | 0.820 |
Why?
|
| Serratia marcescens | 3 | 2011 | 20 | 0.820 |
Why?
|
| Tuberculosis | 3 | 2019 | 595 | 0.810 |
Why?
|
| Ganciclovir | 7 | 2024 | 179 | 0.780 |
Why?
|
| Surgical Wound Infection | 4 | 2014 | 473 | 0.770 |
Why?
|
| Hematology | 1 | 2022 | 101 | 0.770 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2021 | 12 | 0.760 |
Why?
|
| Immune Reconstitution | 1 | 2021 | 25 | 0.750 |
Why?
|
| Immune Sera | 1 | 2021 | 147 | 0.750 |
Why?
|
| Immunization, Passive | 2 | 2021 | 176 | 0.750 |
Why?
|
| Herpesvirus 3, Human | 1 | 2021 | 45 | 0.750 |
Why?
|
| Adenoviridae Infections | 3 | 2017 | 122 | 0.730 |
Why?
|
| Mycoses | 9 | 2023 | 388 | 0.730 |
Why?
|
| Herpesvirus 6, Human | 4 | 2008 | 79 | 0.730 |
Why?
|
| Herpes Zoster | 1 | 2021 | 52 | 0.730 |
Why?
|
| Graft vs Host Disease | 16 | 2023 | 2736 | 0.720 |
Why?
|
| Risk Factors | 31 | 2023 | 18047 | 0.710 |
Why?
|
| DNA Virus Infections | 1 | 2020 | 28 | 0.710 |
Why?
|
| Chemoprevention | 2 | 2019 | 250 | 0.700 |
Why?
|
| Adenovirus Infections, Human | 1 | 2020 | 55 | 0.690 |
Why?
|
| Pandemics | 6 | 2023 | 1624 | 0.690 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2012 | 248 | 0.690 |
Why?
|
| Vaccines | 2 | 2015 | 403 | 0.680 |
Why?
|
| Adrenal Gland Diseases | 1 | 2020 | 72 | 0.680 |
Why?
|
| Palivizumab | 6 | 2018 | 65 | 0.670 |
Why?
|
| Phage Therapy | 1 | 2019 | 23 | 0.670 |
Why?
|
| Metapneumovirus | 2 | 2017 | 58 | 0.670 |
Why?
|
| Cystitis | 2 | 2021 | 106 | 0.660 |
Why?
|
| Leukopenia | 2 | 2018 | 150 | 0.640 |
Why?
|
| Minocycline | 3 | 2011 | 187 | 0.630 |
Why?
|
| Treatment Outcome | 33 | 2024 | 34360 | 0.610 |
Why?
|
| Organ Transplantation | 2 | 2024 | 203 | 0.600 |
Why?
|
| Drugs, Investigational | 1 | 2019 | 135 | 0.600 |
Why?
|
| Acyclovir | 3 | 2018 | 78 | 0.590 |
Why?
|
| Xenon | 3 | 2020 | 19 | 0.580 |
Why?
|
| Clinical Trials as Topic | 8 | 2024 | 3837 | 0.570 |
Why?
|
| Stem Cell Transplantation | 9 | 2020 | 1384 | 0.570 |
Why?
|
| Drug Resistance, Microbial | 2 | 2014 | 217 | 0.560 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2015 | 1283 | 0.560 |
Why?
|
| Texas | 15 | 2020 | 6491 | 0.540 |
Why?
|
| Operating Rooms | 1 | 2017 | 127 | 0.540 |
Why?
|
| Azabicyclo Compounds | 1 | 2016 | 41 | 0.530 |
Why?
|
| Isoxazoles | 1 | 2016 | 82 | 0.530 |
Why?
|
| Cost of Illness | 1 | 2019 | 512 | 0.530 |
Why?
|
| Bacterial Load | 2 | 2017 | 45 | 0.530 |
Why?
|
| Lymphocyte Transfusion | 1 | 2016 | 178 | 0.520 |
Why?
|
| Ceftazidime | 1 | 2016 | 58 | 0.520 |
Why?
|
| Aged, 80 and over | 30 | 2021 | 30849 | 0.520 |
Why?
|
| Gram-Negative Bacterial Infections | 3 | 2014 | 167 | 0.510 |
Why?
|
| Cause of Death | 3 | 2024 | 791 | 0.510 |
Why?
|
| Antibodies, Viral | 7 | 2021 | 1373 | 0.500 |
Why?
|
| Sodium Hypochlorite | 1 | 2015 | 12 | 0.500 |
Why?
|
| Environmental Microbiology | 1 | 2015 | 21 | 0.500 |
Why?
|
| Equipment Contamination | 3 | 2011 | 91 | 0.490 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2015 | 158 | 0.490 |
Why?
|
| Catheter-Related Infections | 5 | 2019 | 272 | 0.490 |
Why?
|
| Child, Preschool | 20 | 2023 | 16888 | 0.490 |
Why?
|
| Herbaspirillum | 1 | 2014 | 6 | 0.490 |
Why?
|
| Interferon-gamma Release Tests | 1 | 2016 | 87 | 0.490 |
Why?
|
| beta-Lactamases | 2 | 2016 | 183 | 0.490 |
Why?
|
| Pharmacogenetics | 1 | 2016 | 263 | 0.480 |
Why?
|
| Viral Load | 5 | 2020 | 488 | 0.470 |
Why?
|
| Aminoglycosides | 2 | 2014 | 224 | 0.470 |
Why?
|
| Health Personnel | 3 | 2020 | 645 | 0.460 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 619 | 0.460 |
Why?
|
| Administration, Inhalation | 4 | 2019 | 298 | 0.460 |
Why?
|
| Drug Contamination | 2 | 2011 | 49 | 0.460 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2015 | 1355 | 0.460 |
Why?
|
| Practice Guidelines as Topic | 3 | 2014 | 2488 | 0.460 |
Why?
|
| Syringes | 3 | 2011 | 43 | 0.460 |
Why?
|
| Drug Resistance, Multiple | 1 | 2014 | 210 | 0.450 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2014 | 109 | 0.450 |
Why?
|
| beta-Lactams | 1 | 2013 | 53 | 0.450 |
Why?
|
| Bronchoalveolar Lavage Fluid | 3 | 2018 | 256 | 0.440 |
Why?
|
| Influenza Vaccines | 2 | 2016 | 654 | 0.430 |
Why?
|
| Genotype | 5 | 2016 | 4015 | 0.420 |
Why?
|
| Anti-Infective Agents | 4 | 2019 | 463 | 0.410 |
Why?
|
| Ribonucleosides | 3 | 2024 | 40 | 0.410 |
Why?
|
| Child | 25 | 2023 | 30372 | 0.400 |
Why?
|
| Environmental Restoration and Remediation | 1 | 2011 | 3 | 0.400 |
Why?
|
| Herpes Simplex | 3 | 2018 | 95 | 0.390 |
Why?
|
| Abdominal Neoplasms | 1 | 2013 | 241 | 0.390 |
Why?
|
| BK Virus | 3 | 2020 | 123 | 0.390 |
Why?
|
| Furunculosis | 1 | 2011 | 8 | 0.390 |
Why?
|
| Patients' Rooms | 1 | 2011 | 13 | 0.380 |
Why?
|
| T-Lymphocytes | 5 | 2022 | 3960 | 0.380 |
Why?
|
| Vancomycin | 2 | 2016 | 285 | 0.380 |
Why?
|
| Transplantation Conditioning | 7 | 2018 | 2309 | 0.380 |
Why?
|
| Immunocompetence | 2 | 2010 | 74 | 0.380 |
Why?
|
| United States | 17 | 2023 | 16336 | 0.380 |
Why?
|
| Disease Transmission, Infectious | 2 | 2011 | 93 | 0.370 |
Why?
|
| Immunity, Cellular | 4 | 2021 | 430 | 0.370 |
Why?
|
| Recurrence | 7 | 2024 | 4890 | 0.360 |
Why?
|
| Catheters, Indwelling | 2 | 2011 | 382 | 0.360 |
Why?
|
| Prospective Studies | 11 | 2024 | 13347 | 0.350 |
Why?
|
| Gastrointestinal Tract | 1 | 2013 | 326 | 0.350 |
Why?
|
| Lung Transplantation | 2 | 2005 | 387 | 0.350 |
Why?
|
| Valine | 1 | 2010 | 182 | 0.350 |
Why?
|
| Viral Fusion Proteins | 3 | 2020 | 88 | 0.350 |
Why?
|
| Oseltamivir | 2 | 2021 | 32 | 0.340 |
Why?
|
| Clostridium Infections | 3 | 2022 | 256 | 0.340 |
Why?
|
| Pneumonia | 4 | 2024 | 764 | 0.340 |
Why?
|
| Rifampin | 2 | 2011 | 205 | 0.340 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 124 | 0.330 |
Why?
|
| Cell- and Tissue-Based Therapy | 5 | 2022 | 386 | 0.330 |
Why?
|
| Lymphoma | 2 | 2009 | 1489 | 0.320 |
Why?
|
| Antigens, Viral | 3 | 2020 | 475 | 0.320 |
Why?
|
| Enterococcus | 3 | 2015 | 60 | 0.320 |
Why?
|
| Lymphopenia | 2 | 2023 | 209 | 0.320 |
Why?
|
| Transplantation, Haploidentical | 2 | 2021 | 161 | 0.310 |
Why?
|
| Simplexvirus | 1 | 2009 | 160 | 0.310 |
Why?
|
| Catheterization, Central Venous | 4 | 2011 | 364 | 0.310 |
Why?
|
| Cohort Studies | 11 | 2021 | 9471 | 0.300 |
Why?
|
| Microbial Sensitivity Tests | 7 | 2021 | 1031 | 0.300 |
Why?
|
| Polyomavirus Infections | 2 | 2020 | 142 | 0.290 |
Why?
|
| Dichlororibofuranosylbenzimidazole | 2 | 2024 | 12 | 0.290 |
Why?
|
| Cyclophosphamide | 4 | 2023 | 3150 | 0.290 |
Why?
|
| Gram-Negative Bacteria | 2 | 2008 | 108 | 0.290 |
Why?
|
| Tumor Virus Infections | 2 | 2020 | 225 | 0.290 |
Why?
|
| Pseudomonas Infections | 3 | 2019 | 158 | 0.290 |
Why?
|
| Viremia | 3 | 2022 | 181 | 0.290 |
Why?
|
| Neuraminidase | 1 | 2007 | 69 | 0.280 |
Why?
|
| Infant | 9 | 2021 | 13891 | 0.280 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2024 | 3376 | 0.270 |
Why?
|
| Antifungal Agents | 7 | 2018 | 859 | 0.270 |
Why?
|
| Critical Care | 2 | 2011 | 797 | 0.260 |
Why?
|
| Aspergillosis | 1 | 2008 | 246 | 0.260 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2020 | 562 | 0.260 |
Why?
|
| Patient Isolation | 2 | 2018 | 25 | 0.260 |
Why?
|
| Postoperative Complications | 4 | 2019 | 5854 | 0.250 |
Why?
|
| Double-Blind Method | 7 | 2020 | 2649 | 0.250 |
Why?
|
| Lung | 3 | 2021 | 3235 | 0.240 |
Why?
|
| Risk Assessment | 10 | 2020 | 7107 | 0.240 |
Why?
|
| Multivariate Analysis | 7 | 2017 | 4358 | 0.230 |
Why?
|
| Logistic Models | 6 | 2019 | 3488 | 0.230 |
Why?
|
| Endocarditis | 2 | 2006 | 139 | 0.230 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2023 | 54 | 0.230 |
Why?
|
| Phenazines | 1 | 2003 | 13 | 0.230 |
Why?
|
| Immunity, Humoral | 2 | 2021 | 90 | 0.230 |
Why?
|
| Gentian Violet | 1 | 2003 | 20 | 0.230 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2009 | 1051 | 0.220 |
Why?
|
| Liver Abscess | 1 | 2003 | 37 | 0.220 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2022 | 7131 | 0.220 |
Why?
|
| Proportional Hazards Models | 5 | 2024 | 5094 | 0.220 |
Why?
|
| Thiazoles | 1 | 2007 | 725 | 0.220 |
Why?
|
| Allografts | 4 | 2021 | 682 | 0.220 |
Why?
|
| Interferon-gamma | 2 | 2019 | 1164 | 0.220 |
Why?
|
| Nasopharynx | 1 | 2023 | 120 | 0.220 |
Why?
|
| Antibodies, Monoclonal | 4 | 2018 | 4457 | 0.220 |
Why?
|
| Gram-Positive Bacteria | 1 | 2003 | 68 | 0.220 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2005 | 365 | 0.220 |
Why?
|
| Stethoscopes | 1 | 2022 | 8 | 0.210 |
Why?
|
| Hand Disinfection | 2 | 2022 | 20 | 0.210 |
Why?
|
| Hand Hygiene | 1 | 2022 | 14 | 0.210 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2021 | 1597 | 0.210 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 4465 | 0.210 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2016 | 189 | 0.210 |
Why?
|
| Candidiasis | 2 | 2002 | 271 | 0.210 |
Why?
|
| Antibodies, Neutralizing | 4 | 2021 | 578 | 0.210 |
Why?
|
| Academic Medical Centers | 2 | 2019 | 697 | 0.200 |
Why?
|
| Epiglottis | 1 | 2002 | 12 | 0.200 |
Why?
|
| Survival Rate | 9 | 2021 | 12474 | 0.200 |
Why?
|
| Dibenzothiepins | 1 | 2021 | 6 | 0.200 |
Why?
|
| Neutropenia | 5 | 2018 | 987 | 0.200 |
Why?
|
| Leukemia, Myeloid | 1 | 2007 | 965 | 0.200 |
Why?
|
| Zygomycosis | 1 | 2002 | 30 | 0.200 |
Why?
|
| Drug Therapy, Combination | 3 | 2016 | 2342 | 0.200 |
Why?
|
| Roseolovirus Infections | 1 | 2002 | 38 | 0.200 |
Why?
|
| Histoplasma | 1 | 2001 | 31 | 0.200 |
Why?
|
| Foscarnet | 2 | 2022 | 17 | 0.200 |
Why?
|
| Tongue | 1 | 2002 | 85 | 0.190 |
Why?
|
| Infectious Mononucleosis | 1 | 2001 | 34 | 0.190 |
Why?
|
| Viral Structural Proteins | 1 | 2021 | 49 | 0.190 |
Why?
|
| Mutation | 3 | 2024 | 15633 | 0.190 |
Why?
|
| DNA Probes | 1 | 2001 | 219 | 0.190 |
Why?
|
| Zika Virus | 1 | 2023 | 150 | 0.190 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2021 | 29 | 0.190 |
Why?
|
| Drug Combinations | 3 | 2016 | 632 | 0.190 |
Why?
|
| Histoplasmosis | 1 | 2001 | 74 | 0.190 |
Why?
|
| Hemorrhagic Disorders | 1 | 2021 | 51 | 0.190 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 2024 | 129 | 0.190 |
Why?
|
| Immunity, Mucosal | 1 | 2021 | 114 | 0.190 |
Why?
|
| Triazines | 1 | 2021 | 118 | 0.190 |
Why?
|
| Rotavirus Infections | 1 | 2003 | 287 | 0.180 |
Why?
|
| Zika Virus Infection | 1 | 2023 | 174 | 0.180 |
Why?
|
| Gastroenteritis | 1 | 2003 | 314 | 0.180 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 4 | 2014 | 130 | 0.180 |
Why?
|
| Benzimidazoles | 3 | 2024 | 432 | 0.180 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 602 | 0.180 |
Why?
|
| Treatment Failure | 3 | 2019 | 1432 | 0.180 |
Why?
|
| Contact Tracing | 1 | 2020 | 62 | 0.180 |
Why?
|
| Immunosuppressive Agents | 3 | 2021 | 1433 | 0.180 |
Why?
|
| Morpholines | 1 | 2021 | 295 | 0.170 |
Why?
|
| Consensus | 1 | 2024 | 1104 | 0.170 |
Why?
|
| Administration, Oral | 3 | 2019 | 1583 | 0.170 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2019 | 15 | 0.170 |
Why?
|
| DNA, Ribosomal | 2 | 2014 | 103 | 0.170 |
Why?
|
| Measles | 1 | 2019 | 34 | 0.170 |
Why?
|
| HLA-DP Antigens | 1 | 2019 | 20 | 0.170 |
Why?
|
| Phylogeny | 1 | 2021 | 852 | 0.170 |
Why?
|
| Intensive Care Units | 4 | 2019 | 748 | 0.160 |
Why?
|
| Acinetobacter Infections | 1 | 2019 | 29 | 0.160 |
Why?
|
| Klebsiella Infections | 1 | 2019 | 64 | 0.160 |
Why?
|
| Catheterization | 2 | 2014 | 436 | 0.160 |
Why?
|
| Pyridones | 1 | 2021 | 366 | 0.160 |
Why?
|
| Urinary Tract Infections | 2 | 2019 | 333 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2021 | 6269 | 0.160 |
Why?
|
| Food Safety | 1 | 2018 | 7 | 0.160 |
Why?
|
| Histocompatibility Testing | 2 | 2019 | 470 | 0.160 |
Why?
|
| Rubulavirus | 1 | 2018 | 8 | 0.160 |
Why?
|
| Respiratory Mucosa | 1 | 2020 | 207 | 0.160 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2015 | 362 | 0.160 |
Why?
|
| Viral Envelope Proteins | 1 | 2020 | 213 | 0.160 |
Why?
|
| Biomarkers | 3 | 2019 | 5162 | 0.160 |
Why?
|
| Venous Thrombosis | 1 | 2002 | 394 | 0.150 |
Why?
|
| Serologic Tests | 1 | 2018 | 142 | 0.150 |
Why?
|
| Survival Analysis | 5 | 2017 | 9311 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 3 | 2015 | 3216 | 0.150 |
Why?
|
| Bone Marrow Transplantation | 2 | 2020 | 1615 | 0.150 |
Why?
|
| Medical Records | 1 | 2019 | 427 | 0.150 |
Why?
|
| Acids, Carbocyclic | 1 | 2017 | 3 | 0.150 |
Why?
|
| Zanamivir | 1 | 2017 | 8 | 0.140 |
Why?
|
| Viruses | 1 | 2018 | 158 | 0.140 |
Why?
|
| Amantadine | 1 | 2017 | 29 | 0.140 |
Why?
|
| Hypoxia | 2 | 2017 | 458 | 0.140 |
Why?
|
| Staphylococcus lugdunensis | 1 | 2016 | 1 | 0.140 |
Why?
|
| Drug Resistance, Multiple, Viral | 2 | 2014 | 9 | 0.140 |
Why?
|
| China | 2 | 2016 | 620 | 0.140 |
Why?
|
| Disease Management | 2 | 2020 | 1118 | 0.140 |
Why?
|
| Guanidines | 1 | 2017 | 61 | 0.140 |
Why?
|
| Time Factors | 10 | 2020 | 13268 | 0.140 |
Why?
|
| HIV Infections | 3 | 2016 | 2224 | 0.140 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 11639 | 0.140 |
Why?
|
| Feces | 2 | 2015 | 819 | 0.140 |
Why?
|
| Colony Count, Microbial | 2 | 2015 | 150 | 0.140 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2016 | 957 | 0.140 |
Why?
|
| Cyclopentanes | 1 | 2017 | 45 | 0.140 |
Why?
|
| History, 21st Century | 1 | 2018 | 447 | 0.140 |
Why?
|
| Picornaviridae Infections | 1 | 2017 | 58 | 0.140 |
Why?
|
| Tissue Donors | 2 | 2023 | 800 | 0.140 |
Why?
|
| Antimicrobial Stewardship | 1 | 2018 | 98 | 0.140 |
Why?
|
| Heart Valve Prosthesis | 1 | 2001 | 434 | 0.140 |
Why?
|
| Aspergillus | 2 | 2008 | 151 | 0.140 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2016 | 42 | 0.140 |
Why?
|
| Health Care Surveys | 2 | 2015 | 445 | 0.140 |
Why?
|
| DNA, Bacterial | 3 | 2014 | 571 | 0.140 |
Why?
|
| Immunologic Factors | 1 | 2020 | 665 | 0.140 |
Why?
|
| Urologic Diseases | 1 | 2016 | 78 | 0.140 |
Why?
|
| Terminology as Topic | 1 | 2019 | 428 | 0.140 |
Why?
|
| Myeloablative Agonists | 2 | 2016 | 381 | 0.140 |
Why?
|
| Sputum | 1 | 2016 | 150 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2018 | 585 | 0.130 |
Why?
|
| Mucor | 1 | 2015 | 18 | 0.130 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2008 | 236 | 0.130 |
Why?
|
| Cluster Analysis | 3 | 2014 | 1080 | 0.130 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2016 | 502 | 0.130 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2007 | 2597 | 0.130 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 1024 | 0.130 |
Why?
|
| Transplantation | 2 | 2013 | 56 | 0.130 |
Why?
|
| Genome, Fungal | 1 | 2015 | 55 | 0.130 |
Why?
|
| Case-Control Studies | 5 | 2010 | 6039 | 0.130 |
Why?
|
| Placebos | 2 | 2020 | 448 | 0.130 |
Why?
|
| Infant, Newborn | 3 | 2021 | 8592 | 0.130 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2016 | 183 | 0.130 |
Why?
|
| Administration, Intravesical | 1 | 2015 | 172 | 0.130 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 489 | 0.130 |
Why?
|
| Length of Stay | 3 | 2019 | 2049 | 0.130 |
Why?
|
| Odds Ratio | 3 | 2017 | 2303 | 0.120 |
Why?
|
| Immunization Schedule | 1 | 2015 | 122 | 0.120 |
Why?
|
| Bronchoscopy | 1 | 2018 | 480 | 0.120 |
Why?
|
| Pyrimidines | 1 | 2007 | 3635 | 0.120 |
Why?
|
| Betaproteobacteria | 1 | 2014 | 6 | 0.120 |
Why?
|
| Burkholderia cepacia | 1 | 2014 | 7 | 0.120 |
Why?
|
| Prevalence | 3 | 2019 | 3399 | 0.120 |
Why?
|
| Hospitalization | 3 | 2019 | 2220 | 0.120 |
Why?
|
| Fungi | 3 | 2008 | 145 | 0.120 |
Why?
|
| Interferons | 1 | 2016 | 300 | 0.120 |
Why?
|
| Microbial Viability | 1 | 2015 | 65 | 0.120 |
Why?
|
| Plasma | 1 | 2015 | 159 | 0.120 |
Why?
|
| Bacteria | 1 | 2019 | 626 | 0.120 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 4868 | 0.120 |
Why?
|
| Mortality | 1 | 2017 | 368 | 0.120 |
Why?
|
| Molecular Typing | 1 | 2014 | 55 | 0.120 |
Why?
|
| Staphylococcus aureus | 3 | 2008 | 560 | 0.120 |
Why?
|
| Prognosis | 7 | 2016 | 22347 | 0.120 |
Why?
|
| Leukocidins | 2 | 2011 | 46 | 0.120 |
Why?
|
| Myelodysplastic Syndromes | 3 | 2022 | 3096 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2016 | 336 | 0.120 |
Why?
|
| Mucormycosis | 1 | 2015 | 112 | 0.120 |
Why?
|
| Antilymphocyte Serum | 1 | 2015 | 230 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 786 | 0.120 |
Why?
|
| Europe | 3 | 2023 | 662 | 0.120 |
Why?
|
| Blood | 1 | 2014 | 159 | 0.120 |
Why?
|
| Exotoxins | 2 | 2011 | 78 | 0.120 |
Why?
|
| Viral Proteins | 1 | 2016 | 443 | 0.110 |
Why?
|
| Animals | 7 | 2022 | 61195 | 0.110 |
Why?
|
| Interleukins | 1 | 2016 | 340 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 2018 | 590 | 0.110 |
Why?
|
| Amphotericin B | 2 | 2007 | 294 | 0.110 |
Why?
|
| Sodium Chloride | 2 | 2011 | 157 | 0.110 |
Why?
|
| Immunization | 1 | 2015 | 402 | 0.110 |
Why?
|
| Central Venous Catheters | 1 | 2014 | 100 | 0.110 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2016 | 421 | 0.110 |
Why?
|
| Calcineurin Inhibitors | 2 | 2023 | 71 | 0.110 |
Why?
|
| Follow-Up Studies | 7 | 2015 | 15265 | 0.110 |
Why?
|
| Sepsis | 2 | 2009 | 668 | 0.110 |
Why?
|
| Bacterial Toxins | 2 | 2011 | 224 | 0.110 |
Why?
|
| Induction Chemotherapy | 1 | 2016 | 672 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 2 | 2024 | 2495 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 5016 | 0.100 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2014 | 320 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2007 | 4921 | 0.100 |
Why?
|
| Data Collection | 1 | 2014 | 642 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2019 | 929 | 0.100 |
Why?
|
| Drug Prescriptions | 1 | 2014 | 312 | 0.100 |
Why?
|
| United States Food and Drug Administration | 2 | 2010 | 342 | 0.100 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 209 | 0.100 |
Why?
|
| Heparin | 2 | 2011 | 361 | 0.100 |
Why?
|
| Respiration, Artificial | 2 | 2019 | 594 | 0.100 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2011 | 15 | 0.100 |
Why?
|
| Anti-HIV Agents | 1 | 2014 | 365 | 0.090 |
Why?
|
| Nephritis, Interstitial | 1 | 2011 | 72 | 0.090 |
Why?
|
| Vomiting | 2 | 2009 | 361 | 0.090 |
Why?
|
| Diet | 1 | 2018 | 1472 | 0.090 |
Why?
|
| Nausea | 2 | 2009 | 537 | 0.090 |
Why?
|
| Secondary Prevention | 1 | 2012 | 335 | 0.090 |
Why?
|
| Alleles | 1 | 2016 | 2398 | 0.090 |
Why?
|
| Perioperative Care | 1 | 2013 | 449 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2016 | 2315 | 0.080 |
Why?
|
| Drug Approval | 1 | 2010 | 183 | 0.080 |
Why?
|
| Parainfluenza Virus 2, Human | 1 | 2008 | 4 | 0.080 |
Why?
|
| Regression Analysis | 2 | 2010 | 1548 | 0.080 |
Why?
|
| Epiglottitis | 1 | 2008 | 16 | 0.080 |
Why?
|
| Virus Shedding | 2 | 2020 | 85 | 0.080 |
Why?
|
| Disease Progression | 3 | 2019 | 6883 | 0.080 |
Why?
|
| Croup | 1 | 2008 | 16 | 0.080 |
Why?
|
| Coronavirus Infections | 1 | 2017 | 648 | 0.080 |
Why?
|
| Mannans | 1 | 2008 | 31 | 0.080 |
Why?
|
| beta-Glucans | 1 | 2008 | 34 | 0.080 |
Why?
|
| Fungemia | 2 | 2015 | 116 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 3968 | 0.080 |
Why?
|
| Mastectomy, Segmental | 1 | 2014 | 1042 | 0.080 |
Why?
|
| Equipment and Supplies | 1 | 2008 | 52 | 0.080 |
Why?
|
| Vitamin B 6 | 1 | 2008 | 19 | 0.080 |
Why?
|
| Sex Factors | 2 | 2021 | 2199 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2016 | 2035 | 0.080 |
Why?
|
| Probability | 2 | 2007 | 876 | 0.080 |
Why?
|
| Salvage Therapy | 1 | 2016 | 2099 | 0.080 |
Why?
|
| Pneumonia, Bacterial | 1 | 2009 | 133 | 0.080 |
Why?
|
| Parvovirus B19, Human | 1 | 2007 | 41 | 0.080 |
Why?
|
| Parvoviridae Infections | 1 | 2007 | 40 | 0.080 |
Why?
|
| Phosphatidylglycerols | 1 | 2007 | 33 | 0.080 |
Why?
|
| Stomatitis, Herpetic | 1 | 2007 | 6 | 0.070 |
Why?
|
| Bacterial Adhesion | 1 | 2008 | 145 | 0.070 |
Why?
|
| Ventilation | 1 | 2007 | 19 | 0.070 |
Why?
|
| Genetic Testing | 1 | 2016 | 1673 | 0.070 |
Why?
|
| Environment, Controlled | 1 | 2007 | 21 | 0.070 |
Why?
|
| Oxazolidinones | 1 | 2008 | 63 | 0.070 |
Why?
|
| Adenoviridae | 1 | 2013 | 1458 | 0.070 |
Why?
|
| Enterococcus faecium | 1 | 2007 | 47 | 0.070 |
Why?
|
| Multiple Myeloma | 1 | 1999 | 2237 | 0.070 |
Why?
|
| Brachytherapy | 1 | 2014 | 1003 | 0.070 |
Why?
|
| Enterococcus faecalis | 1 | 2007 | 55 | 0.070 |
Why?
|
| Endophthalmitis | 1 | 2008 | 82 | 0.070 |
Why?
|
| Phosphatidylcholines | 1 | 2007 | 146 | 0.070 |
Why?
|
| Granulocytes | 1 | 2008 | 232 | 0.070 |
Why?
|
| Hepatitis C, Chronic | 1 | 2012 | 462 | 0.070 |
Why?
|
| Colistin | 1 | 2007 | 33 | 0.070 |
Why?
|
| Acetamides | 1 | 2008 | 115 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2017 | 5021 | 0.070 |
Why?
|
| Herpesvirus 1, Human | 1 | 2007 | 111 | 0.070 |
Why?
|
| Carbapenems | 2 | 2022 | 62 | 0.070 |
Why?
|
| Acute Kidney Injury | 1 | 2014 | 795 | 0.070 |
Why?
|
| Escherichia coli Infections | 1 | 2009 | 259 | 0.070 |
Why?
|
| Immunoglobulin G | 2 | 2021 | 1066 | 0.070 |
Why?
|
| Pneumocystis carinii | 1 | 2006 | 20 | 0.070 |
Why?
|
| Hematologic Diseases | 1 | 2008 | 246 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2014 | 987 | 0.070 |
Why?
|
| Interleukin-2 | 1 | 2009 | 851 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2021 | 5123 | 0.070 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2006 | 68 | 0.070 |
Why?
|
| Joint Diseases | 1 | 2006 | 68 | 0.070 |
Why?
|
| Empyema | 1 | 2006 | 28 | 0.070 |
Why?
|
| APACHE | 1 | 2005 | 93 | 0.060 |
Why?
|
| Methicillin Resistance | 1 | 2006 | 144 | 0.060 |
Why?
|
| Chest Tubes | 1 | 2006 | 119 | 0.060 |
Why?
|
| Bone Marrow | 2 | 2023 | 2394 | 0.060 |
Why?
|
| Candida | 2 | 2008 | 168 | 0.060 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2006 | 118 | 0.060 |
Why?
|
| HLA Antigens | 2 | 2021 | 557 | 0.060 |
Why?
|
| Endocarditis, Bacterial | 1 | 2006 | 134 | 0.060 |
Why?
|
| DNA Fingerprinting | 3 | 2009 | 172 | 0.060 |
Why?
|
| Bacterial Typing Techniques | 3 | 2009 | 141 | 0.060 |
Why?
|
| Blood Transfusion | 1 | 2008 | 592 | 0.060 |
Why?
|
| Histological Techniques | 1 | 2004 | 66 | 0.060 |
Why?
|
| Rituximab | 2 | 2024 | 1561 | 0.060 |
Why?
|
| Age Factors | 2 | 2021 | 5503 | 0.060 |
Why?
|
| Dasatinib | 1 | 2007 | 879 | 0.060 |
Why?
|
| Diarrhea, Infantile | 1 | 2003 | 44 | 0.060 |
Why?
|
| DNA | 2 | 2024 | 2733 | 0.060 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2003 | 82 | 0.060 |
Why?
|
| Pasteurella Infections | 1 | 2003 | 9 | 0.050 |
Why?
|
| Pasteurella multocida | 1 | 2003 | 12 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 16327 | 0.050 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2005 | 370 | 0.050 |
Why?
|
| Xylose | 1 | 2022 | 19 | 0.050 |
Why?
|
| Cats | 1 | 2003 | 167 | 0.050 |
Why?
|
| Escherichia coli | 1 | 2009 | 1219 | 0.050 |
Why?
|
| Hygiene | 1 | 2022 | 30 | 0.050 |
Why?
|
| Bacteriological Techniques | 1 | 2003 | 121 | 0.050 |
Why?
|
| Laboratories | 1 | 2003 | 140 | 0.050 |
Why?
|
| Pulmonary Embolism | 2 | 2006 | 336 | 0.050 |
Why?
|
| Bacteroides | 1 | 2022 | 54 | 0.050 |
Why?
|
| Mucus | 1 | 2022 | 119 | 0.050 |
Why?
|
| Survivorship | 1 | 2023 | 117 | 0.050 |
Why?
|
| Tongue Diseases | 1 | 2002 | 18 | 0.050 |
Why?
|
| Societies | 1 | 2021 | 38 | 0.050 |
Why?
|
| Seasons | 1 | 2003 | 354 | 0.050 |
Why?
|
| Candida glabrata | 1 | 2002 | 48 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2003 | 302 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 13883 | 0.050 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2001 | 71 | 0.050 |
Why?
|
| Mucins | 1 | 2022 | 283 | 0.050 |
Why?
|
| Polysaccharides | 1 | 2022 | 200 | 0.050 |
Why?
|
| Triazoles | 1 | 2005 | 629 | 0.050 |
Why?
|
| RNA, Ribosomal | 1 | 2001 | 84 | 0.050 |
Why?
|
| Administration, Topical | 2 | 2014 | 267 | 0.050 |
Why?
|
| Equipment Reuse | 1 | 2020 | 12 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2021 | 1867 | 0.050 |
Why?
|
| Acute Disease | 2 | 2019 | 2491 | 0.050 |
Why?
|
| Rotavirus | 1 | 2003 | 376 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2021 | 251 | 0.050 |
Why?
|
| Living Donors | 1 | 2021 | 181 | 0.040 |
Why?
|
| Immunoassay | 1 | 2021 | 221 | 0.040 |
Why?
|
| Vero Cells | 1 | 2020 | 146 | 0.040 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 2020 | 51 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2021 | 389 | 0.040 |
Why?
|
| Antibody Affinity | 1 | 2020 | 62 | 0.040 |
Why?
|
| Respiratory System | 1 | 2020 | 127 | 0.040 |
Why?
|
| Comorbidity | 1 | 2007 | 2447 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 64 | 0.040 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2023 | 617 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2002 | 317 | 0.040 |
Why?
|
| Idarubicin | 1 | 2002 | 454 | 0.040 |
Why?
|
| Siblings | 1 | 2021 | 294 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 254 | 0.040 |
Why?
|
| Transplantation Immunology | 1 | 2019 | 103 | 0.040 |
Why?
|
| Oxygen | 1 | 2023 | 783 | 0.040 |
Why?
|
| Molecular Epidemiology | 2 | 2009 | 236 | 0.040 |
Why?
|
| Random Allocation | 1 | 2020 | 715 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2021 | 10092 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 7712 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2022 | 847 | 0.040 |
Why?
|
| Liver | 1 | 2007 | 2994 | 0.040 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 14557 | 0.040 |
Why?
|
| Mexico | 1 | 2017 | 266 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2019 | 471 | 0.040 |
Why?
|
| Hospitals, University | 2 | 2007 | 216 | 0.040 |
Why?
|
| Premedication | 1 | 2017 | 133 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2017 | 250 | 0.040 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2009 | 2434 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 557 | 0.030 |
Why?
|
| Autopsy | 2 | 2007 | 180 | 0.030 |
Why?
|
| Aortic Valve | 1 | 2001 | 648 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 991 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 980 | 0.030 |
Why?
|
| Organizational Policy | 1 | 2016 | 78 | 0.030 |
Why?
|
| Biodiversity | 1 | 2016 | 92 | 0.030 |
Why?
|
| Onychomycosis | 1 | 2015 | 17 | 0.030 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2015 | 33 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2021 | 1980 | 0.030 |
Why?
|
| Coinfection | 1 | 2017 | 195 | 0.030 |
Why?
|
| Cytarabine | 1 | 2002 | 1994 | 0.030 |
Why?
|
| Metagenomics | 1 | 2016 | 120 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 2003 | 1461 | 0.030 |
Why?
|
| Age Distribution | 2 | 2007 | 712 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 9020 | 0.030 |
Why?
|
| Metagenome | 1 | 2016 | 181 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2018 | 1269 | 0.030 |
Why?
|
| Fungal Proteins | 1 | 2015 | 255 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2014 | 82 | 0.030 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2014 | 18 | 0.030 |
Why?
|
| Radiology | 1 | 2019 | 445 | 0.030 |
Why?
|
| HIV Protease Inhibitors | 1 | 2014 | 73 | 0.030 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2014 | 60 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2002 | 985 | 0.030 |
Why?
|
| Remission Induction | 1 | 2019 | 3622 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 306 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 310 | 0.030 |
Why?
|
| Diarrhea | 1 | 2017 | 697 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2019 | 1407 | 0.030 |
Why?
|
| Critical Illness | 2 | 2008 | 748 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2014 | 844 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2012 | 240 | 0.020 |
Why?
|
| Causality | 1 | 2012 | 182 | 0.020 |
Why?
|
| Blood-Borne Pathogens | 1 | 2011 | 13 | 0.020 |
Why?
|
| Risk | 1 | 2015 | 1943 | 0.020 |
Why?
|
| Drug and Narcotic Control | 1 | 2009 | 29 | 0.020 |
Why?
|
| Canada | 1 | 2011 | 438 | 0.020 |
Why?
|
| Isotonic Solutions | 1 | 2009 | 44 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 869 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 16073 | 0.020 |
Why?
|
| Hepacivirus | 1 | 2012 | 405 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2012 | 690 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2015 | 943 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2010 | 579 | 0.020 |
Why?
|
| Drug Industry | 1 | 2009 | 90 | 0.020 |
Why?
|
| Nasal Lavage Fluid | 1 | 2008 | 19 | 0.020 |
Why?
|
| Hoarseness | 1 | 2008 | 25 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 1359 | 0.020 |
Why?
|
| Galactose | 1 | 2008 | 87 | 0.020 |
Why?
|
| Taste Disorders | 1 | 2008 | 17 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 4278 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2012 | 642 | 0.020 |
Why?
|
| Quality Control | 1 | 2009 | 459 | 0.020 |
Why?
|
| Linezolid | 1 | 2008 | 70 | 0.020 |
Why?
|
| Algorithms | 1 | 2019 | 3981 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2008 | 254 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 1348 | 0.020 |
Why?
|
| Hospital Bed Capacity, 300 to 499 | 1 | 2007 | 4 | 0.020 |
Why?
|
| Air Movements | 1 | 2007 | 7 | 0.020 |
Why?
|
| Safety | 1 | 2009 | 471 | 0.020 |
Why?
|
| Air Microbiology | 1 | 2007 | 29 | 0.020 |
Why?
|
| Cough | 1 | 2008 | 121 | 0.020 |
Why?
|
| Saliva | 1 | 2008 | 239 | 0.020 |
Why?
|
| Mouthwashes | 1 | 2007 | 41 | 0.020 |
Why?
|
| Filtration | 1 | 2007 | 90 | 0.020 |
Why?
|
| Vitrectomy | 1 | 2008 | 105 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 6103 | 0.020 |
Why?
|
| Particle Size | 1 | 2007 | 194 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 2349 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 684 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 1182 | 0.020 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2006 | 72 | 0.020 |
Why?
|
| Drug Carriers | 1 | 2007 | 332 | 0.020 |
Why?
|
| Intracranial Embolism | 1 | 2006 | 42 | 0.020 |
Why?
|
| Oncology Service, Hospital | 1 | 2005 | 49 | 0.020 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2007 | 201 | 0.020 |
Why?
|
| Drug Resistance, Fungal | 1 | 2005 | 92 | 0.020 |
Why?
|
| Liposomes | 1 | 2007 | 701 | 0.020 |
Why?
|
| Thromboembolism | 1 | 2006 | 159 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 505 | 0.010 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2006 | 318 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 3276 | 0.010 |
Why?
|
| Carrier State | 1 | 2003 | 89 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2008 | 1048 | 0.010 |
Why?
|
| Fatigue | 1 | 2008 | 1267 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 2309 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 4551 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 6183 | 0.010 |
Why?
|
| Mice | 1 | 2022 | 35473 | 0.010 |
Why?
|
| Quality of Life | 1 | 2015 | 4738 | 0.010 |
Why?
|
| Echocardiography | 1 | 2006 | 1263 | 0.010 |
Why?
|
| Heart | 1 | 2006 | 1261 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2006 | 1474 | 0.010 |
Why?
|